Tools for outcome prediction in patients with community acquired pneumonia

References

• Global, regional, and national age-sex specific all-cause and cause-specific mortality for. 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385:117–171.
   PubMed Web of Science ®Google Scholar
• Almirall J, Bolíbar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population based study. Eur Respir J. 2000;15:757–763.
   PubMed Web of Science ®Google Scholar
• Garibaldi R. Epidemiology of community-acquired respiratory tract infections in adults: incidence, etiology, and impact. Am J Med. 1985;78:32–37.
   PubMed Web of Science ®Google Scholar
• Millett E, Quint J, Smeeth L, et al. Incidence of community-acquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: a population-based study. Plos One. 2013;8:e75131.
   PubMed Web of Science ®Google Scholar
• Fine M, Smith M, Carson C, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. Jama. 1996;275:134–141. Epub 1996 Jan 10.
   PubMed Web of Science ®Google Scholar
• Heron M, Hoyert D, Murphy S, et al. Deaths: final data for 2006. Natl Vital Statrep. 2009;57:1–134.
   PubMedGoogle Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250.
   PubMed Web of Science ®Google Scholar
• S Ewig Birkner N, R, Strauss, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009;64:1062–1069.
   PubMed Web of Science ®Google Scholar
• Woodhead M, Welch C, Harrison D, et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care. 2006;10:S1.
   PubMed Web of Science ®Google Scholar
• Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–79.
   PubMed Web of Science ®Google Scholar
• Carratalà J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med. 2012;172:922–928.
   PubMedGoogle Scholar
• Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. Jama. 2013;309:355–363. Epub 2013 Jan 24.
   PubMed Web of Science ®Google Scholar
• Menendez R, Torres A. Treatment failure in community-acquired pneumonia. Chest. 2007;132:1348–1355. Epub 2007 Oct 16.
   PubMed Web of Science ®Google Scholar
• Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59:960–965. Epub 2004 Nov 02.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Carratalà J. Early and late treatment failure in community-acquired pneumonia. Semin Respir Crit Care Med. 2009;30:154–160.
   PubMed Web of Science ®Google Scholar
• Lim W, Macfarlane J, Boswell T, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001;56:296–301.
   PubMed Web of Science ®Google Scholar
• Charles P, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375–384.
   PubMed Web of Science ®Google Scholar
• Rello J, A R, Lisboa T, et al. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med. 2009;37:456–462. Epub 2008 Dec 31.
   PubMed Web of Science ®Google Scholar
• Knaus W, Draper E, Wagner D. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–829.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med. 1996;22:707–710. Epub PMID 8844239.
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al., America IDSo, Society. AT. Infectious diseases society of America; American thoracic society. infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.
   PubMed Web of Science ®Google Scholar
• Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med. 1998;158:1350–1356. Epub 1998 Jul 30.
   PubMedGoogle Scholar
• Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL study investigators. Community-acquired pneumonia intervention trial assessing levofloxacin. Jama. 2000;283:749–755. Epub 2000 Feb 22.
   PubMed Web of Science ®Google Scholar
• Carratala J, Fernandez-Sabe N, Ortega L, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med. 2005;142:165–172. Epub 2005 Feb 03.
   PubMed Web of Science ®Google Scholar
• Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med. 2005;143(12):881–894. Epub 2005 Dec 21.
   PubMed Web of Science ®Google Scholar
• Renaud B, Coma E, Labarere J, et al. Routine use of the pneumonia severity index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis. 2007;44:41–49. Epub 2006 Dec 05.
   PubMed Web of Science ®Google Scholar
• Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012;16(4):R141. Epub 2012 Jul 31.
   PubMed Web of Science ®Google Scholar
• Lim W, Lewis S, Macfarlane J. Severity prediction rules in community acquired pneumonia: a validation study. Thorax. 2000;55:219–223.
   PubMed Web of Science ®Google Scholar
• Lim WS, Van Der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382.
   PubMed Web of Science ®Google Scholar
• Kwok CS, Loke YK, Woo K, et al. Risk prediction models for mortality in community-acquired pneumonia: a systematic review. Biomed Res Int. 2013;2013:504136. Epub 2013 Nov 15.
   PubMed Web of Science ®Google Scholar
• Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J. 2006;27:151–157. Epub 2006 Jan 03.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Charles PG, Melvani S, et al. Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. Scand J Infect Dis. 2008;40:293–300. Epub 2007 Oct 06.
   PubMed Web of Science ®Google Scholar
• Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med. 2005;118:384–392. Epub 2005 Apr 06.
   PubMed Web of Science ®Google Scholar
• Niederman MS. Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest. 2007;131:1205–1215.
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Williams S, Bowler SD. Australasian respiratory and emergency physicians do not use the pneumonia severity index in community-acquired pneumonia. Respirology (Carlton, Vic). 2013;18:291–296. Epub 2012 Oct 06.
   PubMed Web of Science ®Google Scholar
• Liu JL, Xu F, Zhou H, et al. Expanded CURB-65: a new score system predicts severity of community-acquired pneumonia with superior efficiency. Sci Rep. 2016;18:22911.
   Web of Science ®Google Scholar
• Kolditz M, Ewig S, Schutte H, et al. Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med. 2015;278:193–202. Epub 2015 Jan 20.
   PubMed Web of Science ®Google Scholar
• Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. Jama. 1998;279:1452–1457. Epub 1998 May 26.
   PubMed Web of Science ®Google Scholar
• Akram AR, Chalmers JD, Taylor JK, et al. An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia. Clin Microbiol Infect. 2013;19:1174–1180. Epub 2013 Feb 27.
   PubMed Web of Science ®Google Scholar
• Robins-Browne KL, Cheng AC, Thomas KA, et al. The SMART-COP score performs well for pneumonia risk stratification in Australia’s tropical northern territory: a prospective cohort study. Trop Med Int Health. 2012;17:914–919. Epub 2012 May 19.
   PubMed Web of Science ®Google Scholar
• Pereira JM, Moreno RP, Matos R, et al. Severity assessment tools in ICU patients with 2009 influenza A (H1N1) pneumonia. Clin Microbiol Infect. 2012;18:1040–1048. Epub 2012 Jan 24.
   PubMed Web of Science ®Google Scholar
• Sibila O, Mortensen EM, Redrow G, et al. Evaluation of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Hosp Pract (1995). 2012;40:158–164. Epub 2012 May 23.
   PubMedGoogle Scholar
• Guo Q, Li HY, Zhou YP, et al. CURB-65 score predicted mortality in community-acquired pneumonia better than IDSA/ATS minor criteria in a low-mortality-rate setting. Eur J Clin Microbiol Infect Dis. 2012;31:3281–3286. Epub 2012 Jul 19.
   PubMed Web of Science ®Google Scholar
• Kolditz M, Ewig S, Klapdor B, et al. Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax. 2015;70:551–558. Epub 2015 Mar 19.
   PubMed Web of Science ®Google Scholar
• Richards G, Levy H, Laterre PF, et al. CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS. J Intensive Care Med. 2011;26:34–40.
   PubMedGoogle Scholar
• Aydogdu M, Ozyilmaz E, Aksoy H, et al. Mortality prediction in community-acquired pneumonia requiring mechanical ventilation; values of pneumonia and intensive care unit severity scores. Tuberk Toraks. 2010;58:25–34. Epub 2010 Jun 03.
   PubMedGoogle Scholar
• Belkhouja K, Ben Romdhane K, Ghariani A, et al. Severe pneumococcal community-acquired pneumonia admitted to medical Tunisian ICU. J Infect Chemother. 2012;18:324–331. Epub 2011 Nov 03.
   PubMed Web of Science ®Google Scholar
• Narvaez-Rivera R, Rendon A, Salinas-Carmona M, et al. Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis. BMC Infect Dis. 2012;12:15.
   PubMed Web of Science ®Google Scholar
• Holtfreter B, Bandt C, Kuhn SO, et al. Serum osmolality and outcome in intensive care unit patients. Acta Anaesthesiol Scand. 2006;50:970–977. Epub 2006 Aug 23.
   PubMed Web of Science ®Google Scholar
• Ho KM, Lee KY, Williams T, et al. Comparison of Acute Physiology and Chronic Health Evaluation (APACHE) II score with organ failure scores to predict hospital mortality. Anaesthesia. 2007;62:466–473. Epub 2007 Apr 24.
   PubMed Web of Science ®Google Scholar
• Huang DT, Lisa A. Weissfeld, Kellum JA, et al. GenIMS Investigators. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med. 2008;52:48–58.
   PubMed Web of Science ®Google Scholar
• Shehabi Y, Seppelt I. Pro/Con debate: Is procalcitonin useful for guiding antibiotic decision making in critically ill patients? Crit Care. 2008;12:211.
   PubMed Web of Science ®Google Scholar
• Povoa P. C-reactive protein: a valuable marker of sepsis. Intensive Care Med. 2002;28:235–243. Epub 2002 Mar 21.
   PubMed Web of Science ®Google Scholar
• Sankar V, Webster NR. Clinical application of sepsis biomarkers. J Anesth. 2013;27:269–283. Epub 2012 Oct 31.
   PubMed Web of Science ®Google Scholar
• McLean AS, Tang B, Huang SJ. Investigating sepsis with biomarkers. Bmj. 2015;350:h254. Epub 2015 Jan 30.
   PubMed Web of Science ®Google Scholar
• Menendez R, Martinez R, Reyes S, et al. Stability in community-acquired pneumonia: one step forward with markers?. Thorax. 2009;64:987–992. Epub 200s9 Sep 19.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med. 2008;121:219–225. Epub 2008 Mar 11.
   PubMed Web of Science ®Google Scholar
• Que YA, Virgini V, Lozeron ED, et al. C-reactive protein values at admission predict mortality in patients with severe community-acquired pneumonia caused by Streptococcus pneumoniae that require intensive care management. Infection. 2015;43:193–199. Epub 2015 Mar 04.
   PubMed Web of Science ®Google Scholar
• Povoa P, Teixeira-Pinto AM, Carneiro AH. C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study. Crit Care. 2011;15:R169. Epub 2011 Jul 19.
   PubMed Web of Science ®Google Scholar
• Coelho LM, Salluh JI, Soares M, et al. Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care. 2012;16(2):R53.
   PubMed Web of Science ®Google Scholar
• Bruns AH, Oosterheert JJ, Hak E, et al. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J. 2008;32:726–732. Epub 2008 May 30.
   PubMed Web of Science ®Google Scholar
• Menendez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008;63:447–452. Epub 2008 Feb 05.
   PubMed Web of Science ®Google Scholar
• Lacoma A, Rodriguez N, Prat C, et al. Usefulness of consecutive biomarkers measurement in the management of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2012;31:825–833. Epub 2011 Aug 27.
   PubMed Web of Science ®Google Scholar
• Prucha M, Bellingan G, Zazula R. Sepsis biomarkers. Clin Chim Acta. 2015;440:97–103. Epub 2014 Dec 03.
   PubMed Web of Science ®Google Scholar
• Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10. Epub 2007 Mar 06.
   PubMed Web of Science ®Google Scholar
• Ramirez P, Ferrer M, Marti V, et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med. 2011;39:2211–2217. Epub 2011 Jun 28.
   PubMed Web of Science ®Google Scholar
• Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med. 2006;32:469–472. Epub 2006 Feb 16.
   PubMed Web of Science ®Google Scholar
• Charles PE, Tinel C, Barbar S, et al. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care. 2009;13:R38. Epub 2009 Mar 18.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Valles X, Menendez R, et al. Predicting treatment failure in patients with community acquired pneumonia: a case-control study. Respir Res. 2014;15:75.
   PubMed Web of Science ®Google Scholar
• Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med. 2012;172:715–722. Epub 2012 Jul 12.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. Jama. 2009;302:1059–1066. Epub 2009 Sep 10.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174:84–93. Epub 2006 Apr 11.
   PubMed Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9–19. Epub 2007 Jan 16.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Chiappa V, Briel M, et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011;171:1322–1331. Epub 2011 Aug 10.
   PubMed Web of Science ®Google Scholar
• Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375:463–474. Epub 2010 Jan 26.
   PubMed Web of Science ®Google Scholar
• Assink-De Jong E, De Lange DW, Van Oers JA, et al. Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients–calculated sample size: 1816 patients. BMC Infect Dis. 2013;13:178. Epub 2013 Apr 18.
   PubMed Web of Science ®Google Scholar
• Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014;34:263–273. Epub 2014 Aug 02.
   PubMed Web of Science ®Google Scholar
• Guervilly C, Coisel Y, Botelho-Nevers E, et al. Significance of high levels of procalcitonin in patients with influenza A (H1N1) pneumonia. J Infect. 2010;61:355–358. Epub 2010 Aug 31.
   PubMed Web of Science ®Google Scholar
• Waterer GW, Quasney MW, Cantor RM, et al. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med. 2001;163:1599–1604. Epub 2001 Jun 13.
   PubMed Web of Science ®Google Scholar
• Schluter B, Raufhake C, Erren M, et al. Effect of the interleukin-6 promoter polymorphism (−174 G/C) on the incidence and outcome of sepsis. Crit Care Med. 2002;30:32–37. Epub 2002 Mar 21.
   PubMed Web of Science ®Google Scholar
• Gallagher PM, Lowe G, Fitzgerald T, et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax. 2003;58:154–156. Epub 2003 Jan 30.
   PubMed Web of Science ®Google Scholar
• Zobel K, Martus P, Pletz MW, et al. Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ. BMC Pulm Med. 2012;12:6. Epub 2012 Feb 22.
   PubMed Web of Science ®Google Scholar
• Andrijevic I, Matijasevic J, Andrijevic L, et al. Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia. Ann Thorac Med. 2014;9:162–167.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Zimmerli W, et al. Repeated measurements of endothelin-1 precursor peptides predict the outcome in community-acquired pneumonia. Intensive Care Med. 2011;37:970–980.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Wolbers M, Christ-Crain M, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care. 2010;14:R106.
   PubMed Web of Science ®Google Scholar
• Repaske DR, Medlej R, Gultekin EK, et al. Heterogeneity in clinical manifestation of autosomal dominant neurohypophyseal diabetes insipidus caused by a mutation encoding Ala-1–>Val in the signal peptide of the arginine vasopressin/neurophysin II/copeptin precursor. J Clin Endocrinol Metab. 1997;82:51–56. Epub 1997 Jan 01.
   PubMed Web of Science ®Google Scholar
• Müller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest. 2007;37:145–152.
   PubMed Web of Science ®Google Scholar
• Kolditz M, Halank M, Schulte-Hubbert B, et al. Copeptin predicts clinical deterioration and persistent instability in community-acquired pneumonia. Respir Med. 2012;106:1320–1328. Epub 2012 Jun 27.
   PubMed Web of Science ®Google Scholar
• España PP, Capelastegui A, Bilbao A, et al. PSoPP. Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2012;31:3397–3405.
   PubMed Web of Science ®Google Scholar
• Menéndez R, Martínez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009;64:587–591.
   PubMed Web of Science ®Google Scholar
• Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008;31:349–355. Epub 2007 Oct 26.
   PubMed Web of Science ®Google Scholar
• Salluh JI, Rabello LS, Rosolem MM, et al. The impact of coagulation parameters on the outcomes of patients with severe community-acquired pneumonia requiring intensive care unit admission. J Crit Care. 2011 Oct;26(5):496–501.
   PubMed Web of Science ®Google Scholar
• Remmelts HH, Van De Garde EM, Meijvis SC, et al. Addition of vitamin D status to prognostic scores improves the prediction of outcome in community-acquired pneumonia. Clin Infect Dis. 2012;55:1488–1494.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Marlowe RJ, Mueller B. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review. Clinical Chemistry Laboratory Medicine. 2015;53:521–539. Epub 2014 Sep 26.
   PubMed Web of Science ®Google Scholar
• Alan M, Grolimund E, Kutz A, et al. Clinical risk scores and blood biomarkers as predictors of long-term outcome in patients with community-acquired pneumonia: a 6-year prospective follow-up study. J Intern Med. 2015;278:174–184.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Morgenthaler NG, Struck J, et al. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care. 2005;9:R816–24. Epub 2005 Dec 17.
   PubMed Web of Science ®Google Scholar
• Kruger S, Ewig S, Giersdorf S, et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German competence network, CAPNETZ. Am J Respir Crit Care Med. 2010;182:1426–1434. Epub 2010 Jul 20.
   PubMed Web of Science ®Google Scholar
• Viasus D, Garcia-Vidal C, Simonetti A, et al. Prognostic value of serum albumin levels in hospitalized adults with community-acquired pneumonia. J Infect. 2013;66:415–423.
   PubMed Web of Science ®Google Scholar
• Takada K, Matsumoto S, Kojima E, et al. Predictors and impact of time to clinical stability in community-acquired pneumococcal pneumonia. Respir Med. 2014;108:806–812. Epub 2014 Mar 05.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska A, Nowalk MP, et al. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia. J Gen Intern Med. 2013;28:1157–1164. Epub 2013 Mar 07.
   PubMed Web of Science ®Google Scholar
• Bello S, Lasierra, A.B, Mincholé E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J. 2012;39:1144–1155.
   PubMed Web of Science ®Google Scholar